TECENTRIQ + Avastin® (bevacizumab) Offers a Same-Day Dosing Schedule

A combination therapy with consistent, q3w infusions 1,8

Dosing information for Avastin is based on the IMbrave150 trial; TECENTRIQ was administered q3w in IMbrave150. Visualization of vials is illustrative and does not represent actual vial usage.
IV=intravenous; q2w=every 2 weeks; q3w=every 3 weeks; q4w=every 4 weeks.
 

  • TECENTRIQ should be administered first, followed by Avastin
  • Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
  • If Avastin is discontinued, TECENTRIQ can be administered as 840 mg q2w, as 1200 mg q3w, or as 1680 mg q4w
  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Administer Avastin as an IV infusion
  • First infusion of Avastin: administer infusion over 90 minutes
  • Subsequent infusions: administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated
  • Refer to the Avastin Prescribing Information for Avastin dosage modifications for specific adverse reactions. No dose reductions for Avastin are recommended
Select Important Safety Information for Avastin 8
  • An evaluation for the presence of varices is recommended within 6 months of initiation of Avastin in patients with HCC
  • There is lack of clinical data to support the safety of Avastin in patients with history or risk of variceal bleeding

Dosage modifications from the TECENTRIQ Prescribing Information 1*

Adverse reaction
Severity of adverse reaction
Dosage modifications
Pneumonitis
Grade 2
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 3 or 4
Permanently discontinue
Hepatitis in patients with cancers other than HCC
AST or ALT >3 and ≤8 times ULN or total bilirubin >1.5 and ≤3 times ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT >8 times ULN or total bilirubin >3 times ULN
Permanently discontinue
Hepatitis in patients with HCC
  • AST or ALT is within normal limits at baseline and increases to more than 3 and up to 10 times the ULN
  • AST or ALT is more than 1 and up to 3 times the ULN at baseline and increases to more than 5 and up to 10 times the ULN
  • AST or ALT is more than 3 and up to 5 times the ULN at baseline and increases to more than 8 and up to 10 times the ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT increases to more than 10 times the ULN or total bilirubin increases to more than 3 times the ULN
Permanently discontinue
Colitis or diarrhea
Grade 2 or 3
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4
Permanently discontinue
Endocrinopathies
Grade 2, 3, or 4
Withhold dose until grade 1 or resolved and clinically stable on hormone replacement therapy
Other immune-mediated adverse reactions involving a major organ
Grade 3
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4
Permanently discontinue
Infections
Grade 3 or 4
Withhold dose until grade 1 or resolved
Infusion-related reactions
Grade 1 or 2
Interrupt or slow the rate of infusion
Grade 3 or 4
Permanently discontinue
Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies)
Grade 2 or 3 adverse reaction that does not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Inability to taper corticosteroid
Inability to reduce to less than or equal to prednisone 10 mg per day (or equivalent) within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Recurrent grade 3 or 4 adverse reaction
Recurrent grade 3 or 4 (severe or life-threatening) adverse reaction
Permanently discontinue


ALT=alanine aminotransferase; AR=adverse reaction; AST=aspartate aminotransferase; HCC=hepatocellular carcinoma; ULN=upper limit of normal.
*Refer to the Avastin Prescribing Information for dosage modifications and AR management.
Graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Including, but not limited to, hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus.